Tasly Pharmaceutical Group's (600535.SH) subsidiary, Carter's oral solution of bupropion hydrochloride, has obtained a pharmaceutical registration certificate.
Tasly Pharmaceutical Group (600535.SH) announced that its wholly-owned subsidiary, Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., ...
Tasly Pharmaceutical Group Co., Ltd Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Tasly Pharmaceutical Group 2024 Semi-Annual Report
Summary of Tasly Pharmaceutical Group's 2024 semi-annual report
Tasly Pharmaceutical Group (600535.SH): The net income in the first half of the year was 0.662 billion yuan, a 6.33% decrease year-on-year, with a proposed dividend of 2.6 yuan.
GeLongHui August 23 | Tasly Pharmaceutical Group (600535.SH) announced its interim report for the first half of 2024, with revenue of 4.372 billion yuan, a decrease of 0.46% year-on-year; net income attributable to shareholders of the listed company was 0.662 billion yuan, a decrease of 6.33% year-on-year; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.735 billion yuan, an increase of 6.31% year-on-year; basic earnings per share was 0.4433 yuan. It is proposed to distribute a cash dividend of 2.6 yuan (tax included) for every 10 shares to all shareholders. The revenue decreased by 0.46% compared to the same period last year, with pharmaceutical industry revenue increasing by 4.
Private Companies Are Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Biggest Owners and Were Hit After Market Cap Dropped CN¥1.2b
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): Currently, there is no plan to divest Tasly Pharmaceutical Group's non-traditional chinese medicine business.
China Resources Sanjiu Medical & Pharmaceutical stated in an investor relations event on August 8 that Tasly Pharmaceutical Group's pipeline of traditional Chinese medicine as the core, with biological and chemical medicine as the auxiliary, is complementary to the business layout of modern traditional Chinese medicine. As we expand the modern traditional Chinese medicine business, we will also specialize in biological and chemical medicine, forming a pipeline complementary business layout. We recognize the pipeline layout of Tasly Pharmaceutical Group and will mutually empower each other in the future to promote the stable leading position of Tasly Pharmaceutical Group in innovative research and development of traditional Chinese medicine. Currently, there is no plan to divest non-traditional Chinese medicine business of Tasly Pharmaceutical Group.
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): Tasly Pharmaceutical Group is an excellent enterprise that the company has long-term attention to, with a competitive advantage in the entire industry chain.
On August 8th, China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated in an investor relations event that since the beginning of the 14th Five-Year Plan, the company has been focused on the strategic goal of becoming a leading enterprise in the industry, adhering to the dual driving force of "brand + innovation", continuously improving its business layout, and highly concerned about opportunities to integrate high-quality resources in the industry chain. Tasly Pharmaceutical Group is an excellent enterprise that the company has long been concerned about and has a competitive advantage in the entire industry chain. China Resources Sanjiu Medical & Pharmaceutical is a leading enterprise in the traditional Chinese medicine industry chain, and the strategic layout of the two sides is highly matched. Therefore, the company is very pleased to have such an opportunity to cooperate with Tasly Pharmaceutical Group in terms of equity.
Zhejiang Canaan Technology (300412.SZ): the company's clients include Tasly Pharmaceutical Group, China Resources, etc.
On August 8th, Gelunhui reported that Zhejiang Canaan Technology (300412.SZ) stated on their investor interaction platform that the majority of their customers are well-known international and domestic companies in the pharmaceutical industry, including Tasly Pharmaceutical Group and China Resources.
Hong Kong stocks' abnormal movement: Chinars Pharma (03320) rose another 3% with a premium acquisition of 28% equity of Tasly Pharmaceutical Group. Institutions have raised the company's revenue forecast.
Chinarese Pharma (03320) has risen by more than 3%, as of press time, up 3.3% to HKD 5.63, with a turnover of 39.2174 million HKD.
CR Sanjiu Medical to Buy 28% Stake in Tasly Pharma for Over 6 Billion Yuan; Tasly Shares Down 4%
Chinacores pharma: China Resources Sanjiu Medical & Pharmaceutical plans to spend about 6.212 billion yuan to acquire 28% equity of Tasly Pharmaceutical Group.
China Resources Pharma (03320) announced that on August 4, 2024, China Resources Sanjiu entered into a share purchase agreement with the seller. Accordingly, China Resources Sanjiu has conditionally agreed to purchase and the seller has conditionally agreed to sell a total of 0.418 billion shares of Tasly Pharmaceutical Group (equivalent to 28% equity of Tasly Pharmaceutical Group as at the date of this announcement) at a proposed price of RMB 14.85 per share, or a total consideration of approximately RMB 6.212 billion. After completion, China Resources Sanjiu will hold a 28% stake in Tasly Pharmaceutical Group and become its largest shareholder, while Tasly Pharmaceutical Group will serve as a non-wholly owned subsidiary of the company.
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) plans to acquire Tasly Pharmaceutical Group (600535.SH) to achieve high-quality development of the traditional Chinese medicine industry chain.
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) has announced plans to acquire Tasly Pharmaceutical Group and its subsidiaries through cash payments.
Tasly Pharmaceutical Group (600535.SH): T89 prevention and treatment of acute high-altitude reaction adaptive syndrome received related meeting minutes of clinical trials by the USA FDA.
On August 4th, Gelunhui learned that Tasly Pharmaceutical Group (stock code: 600535.SH) announced that its compound salvia miltiorrhiza droplet pill (FDA clinical trial application code is T89) for the prevention and treatment of acute altitude sickness has begun the phase III clinical trial of the US FDA (US Food and Drug Administration) in 2021. For more details, please see the company's "Announcement on the Progress of Applying for the New Drug Listing Clinical Trial of T89 for the Prevention and Treatment of Acute Altitude Sickness in the United States and Risk Tips" (announcement No.: LIN2021-040). The company held a meeting with the FDA on the major progress of the clinical trial and recently received the meeting minutes. The compound
Express News | Tasly Pharmaceutical Says Trading in Shares to Resume on Aug 5
Express News | Tasly Pharmaceutical Says Controlling Shareholder Will Change to China Resources Sanjiu, Actual Controller Will Be China Resources After Stake Transfer
Express News | Tasly Pharmaceutical Says Controlling Shareholder, Parties Acting in Concert Agree to Sell 28% Stake in the Company to China Resources Sanjiu Medical for 6.2 Bln Yuan
Tasly Pharmaceutical Group (600535.SH) controlling shareholder is expected to change to China Best, and the trading will be suspended from August 1st.
Tasly Pharmaceutical Group (600535.SH) has announced that on August 4, 2024, its controlling shareholder Tasly Pharmaceutical Group and ...
Tianjin Lisheng Pharmaceutical (002393.SZ): Its subsidiary Tasly Pharmaceutical Group is planning to transfer its shares of the controlling subsidiary Tasly.
On August 2, Gelonhui reported that Tianjin Lisheng Pharmaceutical (002393.SZ) announced that its subsidiary Tianjin Central Pharmaceutical Co., Ltd. (hereinafter referred to as "Central Pharmaceutical") received a notification from its equity participation company Tasly Biomedical Industry Group Co., Ltd. (hereinafter referred to as "Tasly Group") that it is planning a share transfer of its holding subsidiary Tianjin Tasly Pharmaceutical Group Co., Ltd. (Securities code: 600535, securities abbreviation: Tasly), which may lead to a change in control of Tianjin Tasly Pharmaceutical Group Co., Ltd. Central Pharmaceutical, a subsidiary of the company, holds 12%.
Are Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Mixed Financials Driving The Negative Sentiment?
No Data
No Data